Apollomics is a clinical-stage biopharmaceutical company focused on oncology therapeutics that leverage immunological mechanisms and targeted molecular pathways to treat cancer. The company's lead candidate, Vebreltinib (APL-101), is an oral, selective c-Met inhibitor currently in Phase 2 trials for non-small cell lung cancer and solid tumors with MET dysregulation. The pipeline also includes APL-102, a multi-target tyrosine kinase inhibitor in Phase 1 development, and APL-122, a tumor inhibitor targeting ErbB1/2/4 signaling pathways in Phase 1 dose escalation studies for brain cancers. Additionally, the company is developing immuno-oncology candidates designated APL-501, APL-502, and APL-801.
As a pre-revenue, clinical-stage company, Apollomics operates with a small workforce of 13 full-time employees and is headquartered in Foster City, California. The company was founded in 2015 and went public on Nasdaq. With no established revenue streams, the company's financial performance is driven by research and development spending and clinical trial advancement rather than product commercialization.
No 10-K filings found.